Skip to search formSkip to main contentSkip to account menu

1 ML certolizumab pegol 200 MG/ML Prefilled Syringe [Cimzia]

Known as: CERTOLIZUMAB PEGOL 200 mg in 1 mL SUBCUTANEOUS INJECTION, SOLUTION [Cimzia], Cimzia 200 MG in 1 ML Prefilled Syringe, Cimzia 200 MG per 1 ML Prefilled Syringe 
National Institutes of Health

Related topics

Related topics

8 relations

Broader (1)

1 ML certolizumab pegol 200 MG/ML Prefilled Syringe
CimziaPrefilled SyringeSodium AcetateSodium Chloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Certolizumab Pegol for Psoriasis and Psoriatic Arthritis
Purpose of Review The purpose of this review is to provide an overview of the use of certolizumab pegol (Cimzia®, UCB S.A.) for… 
2018
2018
Anti-Tumor Necrosis Factor α Therapeutics Differentially Affect Leishmania Infection of Human Macrophages
Tumor necrosis factor α (TNFα) drives the pathophysiology of human autoimmune diseases and consequently, neutralizing antibodies… 
2017
2017
Certolizumab pegol administration devices: a profile of their use and usability
Certolizumab pegol (Cimzia®), a tumour necrosis factor-α (TNF) antagonist, is an effective and well-tolerated option for the… 
2014
2014
Abciximab (Reopro®), Bevacizumab (Avastin®), Certolizumab Pegol (Cimzia®), Eculizumab (Soliris®), Natalizumab (Tysabri®)
2013
2013
Antibody fragments: Prolonging circulation half-life special issue-antibody research
Antibodies are currently the fastest growing class of therapeutic proteins. When antibody fragments are included, there are over… 
Review
2013
Review
2013
A review of cost–effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis
Rheumatoid arthritis (RA) is an autoimmune chronic disease which is associated with an increasing disability in patients and high… 
Review
2010
Review
2010
2 TNF-α blockers in inflammatory bowel diseases : Practical consensus recommendations and a user ’ s guide
More than seventy years after their initial characterisation, the aetiology of inflammatory bowel diseases remains elusive. A… 
2009
2009
Flexible Manufacturing Facility for Biopharmaceuticals
Monoclonal antibodies (mAbs) have the potential to treat a wide range of diseases. They possess the ability to bind target… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)